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Meenakshi Jolly*, Winston Sequeira and Joel A BlockDear editors
We read with interest the recently published paper titled
Patient-Reported Outcome Measures for Systemic Lupus
Erythematosus Clinical Trials: a Review of Content Valid-
ity and Psychometric Performance [1]. We applaud the
authors for undertaking this study to identify the relative
strengths and weaknesses of patient reported outcome
(PRO) tools being currently used in systemic lupus
erythematosus (SLE).
We feel that some of the information provided on
LupusPRO is inadvertently misleading, while some
pertinent information on SF36 and LupusQoL may have
been not discussed. The conclusions thus drawn may
undermine the utility of LupusPRO and favorably bias
the readers towards SF36 or LupusQoL.
Conceptual content validity: The authors note that the
current literature is lacking on evidence on importance of
concepts related to “treatment satisfaction”, “adherence”
and “impact of flares” and are thus “future considerations”.
LupusPRO [2] included all three items in the item pool
derived from patient feedback. “Treatment satisfaction”
and “Flares” are represented in the “Satisfaction with
Care” and “Lupus Symptoms” domains. Adherence tied
closely with medications and their side effects, is repre-
sented in “Lupus Medications” domain. Furthermore, we
note several concepts that LupusPRO covers, but were
not reported in Table two. These include “marks on skin”,
and “sleep”. “Leisure activities” is reflected in LupusPRO
item “kinds of tasks or activities I could perform”, while
“weight gain”, “looking sick” are captured in LupusPRO
body image items on “appearance changes”. LupusPRO
thus reflects 14/27 concepts listed in the table. Addition-
ally, LupusPRO identifies with other concepts, some
identified by the authors (not listed in the Table), and
include “fear that disease would change”, “control”,
“caring for children”, “fulfilling their role in family”,
”progression of career”, “receiving support”, “ability to
conceive or have children”, “flares”, “medication side
effects” and ‘satisfaction with care”. Others have also* Correspondence: Meenakshi_jolly@rush.edu
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functioning, chronicity of disease, drugs, family support,
functions related to pregnancy, need for medications and
side effects of medications to be important concepts for
SLE [3,4]. Similar to LupusQoL, we did identify import-
ance of relationships with family, friends, intimate partner
and effects on sex. As the tool has undergone further
validation studies, using clinimetric and psychometric ap-
proaches, these items were not be ranked highly and were
dropped. Receiving support from partner/family or friends
was considered more important and were retained. Lupu-
sPRO’s face validity has been tested since the initial
publication, in two focus groups independently, during
the development of the lupus impact tracker [5]. Other
conceptual coverage errors noted in Table two pertain to
conceptual coverage of “weakness”, “sleep”, “relationships”,
“work disability” and “economic impact” by SF36. Hence,
the generalization that SF-36, LupusQoL and SLEQOL
demonstrated greatest level of conceptual coverage as
compared to other tools seems erroneous.
Other psychometric properties: LupusPRO has excellent
construct validity against EQ5D, SF-36, depression and
body image tools in the original English version, as well as
in various languages and regions [2,6-10]. It is responsive
to change against self-reported change in health status [2],
physician global assessment [2,11,12], BILAG [2], LFA
defined flare [2], SLEDAI [11,12] and SELENA Flare Index
[11,12]. SLEQOL, LupusPRO, LupusQoL [13,14] and SF-
36 [15] have been noted to have high floor/ceiling effects
(>15%). SF-36 has been reported to have high floor and
ceiling effects in several diseases [16-18], and is used
widely in research and clinical trials, including SLE. Infact,
floor and ceiling effects of SF-36 were reported in the
SLEQOL development study among SLE patients [15].
The authors should note that LupusQoL and LupusPRO
have been cross culturally validated in several languages
and regions, and continue to show fair psychometric
properties. In addition, LupusPRO is the only tool thus far
to demonstrate measurement equivalence of the tool
across languages and regions [19]. The statement that only
L-QoL and LupusQoL had sufficient evidence of validity
for SLE population is incorrect. Perhaps the authorsd. This is an Open Access article distributed under the terms of the Creative
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Item formatting: Though the authors differ in opinion,
we feel that wording of LupusQoL items 10, 11 and 15
of LupusQoL may be confusing to the patient about the
concept/s being measured. For example, item 10, inter-
ference of sleep by pain from lupus is being sought. A
patient may have difficulty ascribing causality of the pain
to lupus, and then to their sleep. In addition, a lupus
patient with sleep interference, but from lupus related
fatigue, depression or anxiety may endorse the item.
A tool with low ceiling and floor effects is preferable;
however, not every concept measured has a true hier-
archy of difficulty or ability. Furthermore, the domain
may be measuring the range of the concept that is
appropriate for the selected population. We need further
studies to explore and understand this issue. Greater
collaboration would lead us to further patient reported
outcomes research and clinical trials in SLE to improve
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